AbbVie witnessed notable upward momentum with significant intraday volatility as positive clinical updates from its core immunology franchise bolstered investor confidence. The biopharmaceutical giant presented detailed Phase 3 AFFIRM study data at the American College of Gastroenterology annual meeting, demonstrating robust clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with Crohn’s disease. These findings reinforced expectations that expanding indications for Skyrizi and Rinvoq will continue to effectively absorb revenue erosion from legacy blockbuster Humira, supporting long-term commercial durability in inflammatory bowel disease.

Market sentiment was further supported by favorable Wall Street commentary and…